Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab)
Insight into the mechanism of laquinimod action.
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Molecular characterization of a peripheral receptor for cannabinoids.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
Advanced Structural and Functional Brain MRI in Multiple Sclerosis.
Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Data supporting the role of Fyn in initiating myelination in the peripheral nervous system.
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
Studying both sexes: a guiding principle for biomedicine.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Information for healthcare professionals: Rituximab
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Biogen Idec reports death of patient on its MS pill
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Pages